Advertisement

Current Clinical Progress — Podophyllotoxins

  • Brian F. Issell
Part of the Developments in Oncology book series (DION, volume 23)

Abstract

Podophyllotoxin is a compound derived from the roots or rhyzomes of certain plants of the genus Podophyllum (Mandrake, American May apple). VP-16, or etoposide, and VM-26, or teniposide, are semisynthetic derivatives of podophyllotoxin. They differ from the parent compound podophyllotoxin and other classical spindle poisons such as colchicine, vincristine, and vinblastine by not interacting with tubulin or interfering with microtubule assembly (1).

Keywords

Small Cell Lung Cancer Testicular Cancer Small Cell Carcinoma Salvage Setting Testicular Cancer Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Locke, J. D., Horwitz, S. B.: Effect of VP-16-213 on Microtubule Assembly in vitro and Nucleoside Transport in HeLa Cells. Biochemistry 15: 5435, 1976a.CrossRefGoogle Scholar
  2. 2.
    Comis, R. L.: Small Cell Carcinoma of the Lung. Cancer Treat. Rev. 9: 237–258, 1982.PubMedCrossRefGoogle Scholar
  3. 3.
    Cohen, M. H., Broder, L. E., Fossieck, B. E., Ihde, D. C., Minna, J. D.: Phase II Clinical Trial of Weekly Administration of VP-16-213 in Small Cell Bronchogenic Carcinoma. Cancer Treat. Rep. 61: 489–490, 1977.PubMedGoogle Scholar
  4. 4.
    Tucker, R. K., Ferguson, A., VanWyk, C., Sealy, R., Hewitsen, R., Levin, W.: Chemotherapy of Small Cell Carcinoma of the Lung with VP-16-213. Cancer 41: 1710–1714, 1978.PubMedCrossRefGoogle Scholar
  5. 5.
    Tempero, M., Kessinger, A., Lemon, H. M.: VP-16-213 Therapy in Patients with Small Cell Carcinoma of the Lung After Failure on Combination Chemotherapy. Cancer Clin. Trials 4: 155–157, 1981.PubMedGoogle Scholar
  6. 6.
    Evans, W. K., Osoba, D., Feld, R., Shephard, F. A.: VP-16 Alone and in Combination with Cisplatin (P) for Relapse in Small cell Lung Cancer (SCLC). Proc. The III World Conference on Lung Cancer, p. 218, 1982.Google Scholar
  7. 7.
    Tinsley, R., Comis, R., DiFino, S., Ginsberg, S., Gullo, J., Hickes, R., Poiesz, B., Rudolph, A., Issell, B., Lee, F.: Potential Clinical Synergy Observed in the Treatment of Small Cell Lung Cancer (SCLC) with Cisplatin (P) and VP-16–213 (V). Proc. ASCO 2: 198, 1983.Google Scholar
  8. 8.
    Lopez, J. A., Mann, J., Grapski, R., Krikorian, J. G.: Salvage Chemotherapy of Refractory Small Cell Lung Cancer (SCLC) with VP-16 and Cis-Platinum (DDP). Proc. ASCO 1: 151, 1982.Google Scholar
  9. 9.
    U.S. Dept. Health and Human Service. Compilation of Experimental Cancer Therapy Protocol Summaries, 7th edition, 1983.Google Scholar
  10. 10.
    Aisner, J., Whitacre, M., VanEcho, D. A., Wesley, M., Wiernik, P.H.: Doxorubicin, Cyclophosphamide and VP-16-213 (ACE) in the Treatment of Small cell Lung Cancer. Cancer Chemother. Pharmacol. 7: 187–193, 1982.PubMedGoogle Scholar
  11. 11.
    Woods, R. L., Fox, R. M., Trattersall, M. H. N.: Treatment of Small Cell Bronchogenic Carcinoma with VM-26. Cancer Treat. Rep. 63: 2011, 1979.PubMedGoogle Scholar
  12. 12.
    Fitzharris, B. M., Kaye, S. B., Saverymuttu, S., Newlands, E. S., Barrett, A., Peckham, M. J., McElwain, T.J.: VP-16-213 as a Single Agent in Advanced Testicular Tumors. Eur. J. Cancer 16: 1193, 1980.PubMedGoogle Scholar
  13. 13.
    Williams, S. D., Einhorn, L. H., Greco, F. A., Oldham, R., Fletcher, R.: VP-16-213 Salvage Therapy for Refractory Germinal Neoplasms. Cancer 46: 2154–2158, 1980.PubMedCrossRefGoogle Scholar
  14. 14.
    Bender, R. A., Anderson, T., Fisher, R. T., Young, R. C.: The Activity of the Epipodophyllotoxin VP-16 in the Treatment of Combination Chemotherapy Resistant Non-Hodgkin’s Lymphoma. Am. J. Hematol. 5: 203, 1978.PubMedCrossRefGoogle Scholar
  15. 15.
    Cabanillas, F., Hagemeister, F. B., Bodey, G. P., Freireich, E. J.: IMVP- 16: An Effective Regimen for Patients with Lymphoma who have Relapsed after Initial Combination Chemotherapy. Blood 60: 693–697, 1982.PubMedGoogle Scholar
  16. 16.
    Santoro, A., Bonfante, V., Bonadonna, G.: Third-Line Chemotherapy with CCNU, Etoposide and Prednimustine (CEP) in Hodgkin’s Disease (HD) Resistant to MOPP and ABVD. Proc. ASCO 1: 165, 1982.Google Scholar
  17. 17.
    Fisher, R. I., DeVita, V. T., Huybbard, S. M., Longo, D. L., Wesley, R., Chabner, B. A., Young, R. C.: Diffuse Aggressive Lymphomas: Increased Survival After Alternating Flexible Sequences of ProMACE and MOPP Chemotherapy. Annals of Int. Med. 98: 304–309, 1983.Google Scholar
  18. 18.
    Chiuten, D. F., Bennett, J. M., Creech, R. H., Glick, J., Falkson, G., Brodovsky, H. S., Begg, C. G., Muggia, F. M., Carbone, P. O.: VM-26, A New Anticancer Drug with Effectiveness in Malignant Lymphoma: An Eastern Cooperative Oncology Group Study (EST 1474). Cancer Treat. Rep 63: 7, 1979.PubMedGoogle Scholar
  19. 19.
    The Australian and New Zealand Lymphoma Cooperative Chemotherapy Study Group: Comparison of the Use of Teniposide and Vincristine in Combination Chemotherapy for Non-Hodgkinfs Lymphoma. Cancer Treat. Rep. 66: 49–55, 1982.Google Scholar
  20. 20.
    Rivera, G., Dahl, G. V., Bowman, W. P., Avery, T. L., Wood, A., Aur, R. J.: VM-26 and Cytosine Arabinoside Combination Chemotherapy for Initial Induction Failures in Childhood Lymphocytic Leukemia. Cancer 46: 1727, 1980.Google Scholar
  21. 21.
    Bernasconi, C., Lazzarino, M., Morra, E.: The Use of an Epipodophyllotoxin Derivative (VP-16-213) in the Treatment of Acute Monocytic and Myelomonocytic Leukemias. In: Stacher, A., Hocker, P. (Hrsg) Erkrankungen der Myelopoese-Leukemien, Myeloproliferatives Syndrom, Polyzythamie. Urban and Schwarzenerg, Muchen, Berlin, S 224.Google Scholar
  22. 22.
    Hayes, F. A., Green, A. A., Casper, J., Cornet, J., Evans, W. E.: Clinical Evaluation of Sequentially Scheduled Cisplatin and VM-26 in Neuroblastoma: Response and Toxicity. Cancer 48: 1715–1718, 1981.PubMedCrossRefGoogle Scholar
  23. 23.
    Spremulli, E., Schulz, J. J., Speckhart, V. J., Wampler, G. L.: Phase II Study of VM-26 in Adult Malignancies. Cancer Treat. Rep. 64: 147, 1980.PubMedGoogle Scholar
  24. 24.
    Gerosa, M. S., DiStefano, E., Olivi, A.: VM-26 Monochemotherapy Trial in the Treatment of Recurrent Supratentorial Gliomas: Preliminary Report. Surg. Neurol. 15: 128, 1981.CrossRefGoogle Scholar
  25. 25.
    Sweet, D. L., Hendler, F. J., Hanlon, K., Hekmatpanah, J., Griem, M. L., Duda, E. E., Mulligan, B., Wollman, R. L.: Treatment of Grade III and IV Astrocytomas with BCNU Alone and in Combination with VM-26 Following Surgery and Radiation Therapy. Cancer Treat. Rep. 63: 1707–1711, 1979.PubMedGoogle Scholar
  26. 26.
    Schell, F. C., Yap, H. Y., Hortobagyi, G. N., Issell, B., Esparza, L.: Phase II Study of VP-16-213 (Etoposide) in Refractory Metastatic Breast Carcinoma. Cancer Chemother. Pharmacol. 7: 223–225, 1982.PubMedCrossRefGoogle Scholar
  27. 27.
    Vaughn, C. B., Greb, E. M., Lockhard, C., Groshko, G., Enochs, K., Duffin, H., Demitrish, M.: VP-16 and Adriamycin in Patients with Advanced Breast Cancer. Am. J. Clin. Oncol. (CCT) 5: 505–507, 1982.Google Scholar
  28. 28.
    Konits, P. H., VanEcho, D. A., Aisner, J., Morris, D., Wiernik, P. H.: Doxorubicin Plus VP-16-213 for the Treatment of Refractory Breast Carcinoma. Am. J. Clin. Oncol. (CCT) 5: 515–519, 1982.Google Scholar
  29. 29.
    Laubenstein, L. J., Krigel, R. L., Hymes, K. B., Muggia, F. M.: Treatment of Epidemic Kaposi’s Sarcoma with VP-16-213 (Etoposide) and a Combination of Doxorubicin, Bleomycin, and Vinblastine (ABV). Proc. ASCO 2: 228, 1983.Google Scholar
  30. 30.
    Commers, J. R., Foley, J. F.: Pulmonary Hyaline Membrane Disease Occurring in the Course of VM-26 Therapy. Cancer Treat. Rep. 63: 1093, 1979.Google Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston 1984

Authors and Affiliations

  • Brian F. Issell

There are no affiliations available

Personalised recommendations